RESUMEN
PURPOSE: We aimed to evaluate the near-final height (nFHt) in a large cohort of pediatricpatients with growth hormone deficiency (GHD) and to elaborate a new predictive method of nFHt. METHODS: We recruited GHD patients diagnosed between 1987 and 2014 and followed-up until nFHt. To predict the values of nFHt, each predictor was run in a univariable spline. RESULTS: We enrolled 1051 patients. Pre-treatment height was -2.43 SDS, lower than parental height (THt) (-1.09 SDS, p < 0.001). The dose of recombinant human GH (rhGH) was 0.21mg/kg/week at start of treatment. nFHt was -1.08 SDS (height gain 1.27 SDS), higher than pre-treatment height (p < 0.001) and comparable to THt. 1.6% of the patients were shorter than -2 SDS from THt. The rhGH dose at nFHt was 0.19 mg/kg/week, lower than at the start (p < 0.001). The polynomial regression showed that nFHt was affected by gender, THt, age at puberty, height at puberty, age at the end of treatment (F = 325.37, p < 0.0001, R2 87.2%). CONCLUSION: This large national study shows that GHD children can reach their THt. The rhGH/kg/day dose significantly decreased from the start to the end of the treatment. Our model suggests the importance of a timely diagnosis, possibly before puberty, the beneficial effect of long-term treatment with rhGH, and the key-role of THt. Our prediction model has a very acceptable error compared to the majority of other published studies.
Asunto(s)
Enanismo Hipofisario , Hormona de Crecimiento Humana , Estatura , Niño , Estudios de Cohortes , Enanismo Hipofisario/diagnóstico , Enanismo Hipofisario/tratamiento farmacológico , Enanismo Hipofisario/epidemiología , Hormona del Crecimiento/uso terapéutico , Humanos , PubertadRESUMEN
BACKGROUND: Triptorelin, a gonadotropin releasing hormone analogue, can be administered to postpubertal female individuals with cancer who receive chemotherapy to obtain menstrual suppression and decrease the risk of hemorrhage caused by thrombocytopenia. Our goal was to assess whether triptorelin also has a protective role against the gonadotoxicity of chemotherapy. PATIENTS AND METHODS: This retrospective observational study includes all postmenarchal female patients who presented to our Unit from 2000 to 2015 and received chemotherapy for cancer. They were administered depot triptorelin. We evaluated long-term ovarian function in order to detect clinical signs of ovarian damage, miscarriages, and pregnancies. Laboratory follow-up consisted in dosing serum follicle stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone. Ultrasound of the ovaries was performed as well. RESULTS: Of 36 evaluable patients, 9 received hematopoietic stem cell transplantation (HSCT). The remaining 27 patients maintained normal ovarian function at clinical, laboratory, and ultrasound assessment. Five of them achieved spontaneous physiological pregnancy. Four of the 9 patients who underwent HSCT developed premature ovarian failure. CONCLUSION: Our study suggests that gonadotropin releasing hormone-a administered during chemotherapy can prevent premature ovarian failure in patients treated without HSCT and that it is not enough to preserve the ovarian function during HSCT. Hence, a prospective randomized trial with a larger population would be recommended.
Asunto(s)
Antineoplásicos/efectos adversos , Preservación de la Fertilidad , Neoplasias/tratamiento farmacológico , Ovario , Insuficiencia Ovárica Primaria , Pamoato de Triptorelina/administración & dosificación , Adolescente , Antineoplásicos/administración & dosificación , Niño , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Estudios de Seguimiento , Humanos , Hormona Luteinizante/sangre , Neoplasias/sangre , Neoplasias/fisiopatología , Ovario/metabolismo , Ovario/fisiopatología , Insuficiencia Ovárica Primaria/sangre , Insuficiencia Ovárica Primaria/inducido químicamente , Insuficiencia Ovárica Primaria/fisiopatología , Insuficiencia Ovárica Primaria/prevención & control , Progesterona/sangre , Prolactina/sangre , Estudios RetrospectivosRESUMEN
Background Cystic fibrosis related diabetes is a complication of cystic fibrosis (CF). Aim of our study was to evaluate the effects of insulin therapy in overt diabetics or pre-diabetics CF patients on BMI and respiratory function. Methods We selected a sample of 17 insulin treated patients (Group T) and a sample of 17 CF control patients with normal glucose metabolism (Group C). Group T was also subdivided into overt diabetic patients and pre-diabetic patients (IGT, INDET). For treated patients an observation period was established from the first insulin administration to 12 months. For control patients, a comparable year of observation was chosen. Data regarding BMI, FVC, FEV1 and PEF were collected at time 0, and at time 12. The number of hospital admissions for infectious episodes during the year of observation and during the preceding year were recorded for Group T patients. Results The results showed a significant increase in BMI in treated patients compared to control, specially for overt diabetics. The study of spirometric parameters showed a significant improvement of PEF, the main effort-dependent respiratory index, specially for over diabetics, suggesting a hypothetical positive impact of the insulin anabolic action on the magnitude of expiratory effort. In contrast, the study of infectious episodes revealed a significant reduction of hospital admissions in pre diabetic treated patients. Conclusion Overall, our study focuses on the importance of glycemic monitoring during the early stages of CF disease and on the advantage of insulin treatment in the early stages of glucose alteration .
Asunto(s)
Fibrosis Quística , Diabetes Mellitus , Humanos , Fibrosis Quística/complicaciones , Fibrosis Quística/tratamiento farmacológico , Estudios Retrospectivos , Prueba de Tolerancia a la Glucosa , Insulina/uso terapéutico , Diabetes Mellitus/tratamiento farmacológico , GlucosaRESUMEN
Puberty represents a milestone during a person's life and is characterized by several physical and psychological changes which end with the achievement of sexual maturation and of fertility. Puberty onset depends on a series of sophisticated, not completely understood, mechanisms certainly involving Gonadotropin-Releasing Hormone (GnRH) and its effects on pituitary gonadotropins. As recent evidence has demonstrated that pubertal timing deeply affects future adult health life, many efforts have been performed in order to clarify the exact actors involved in the onset and progression of puberty. Genetic factors are undoubtedly essential players in the regulation of pubertal development, accounting for approximately 50-80% of its variability. Mutations in genes such as KISS1, MKRN3, and DLK1 have been associated with central precocious puberty. Interestingly, a possible involvement of epigenetic mechanisms has been proposed as additional element able to affect pubertal phase. Environmental factors have recently attracted much attention. Indeed, an overall decrease in the age of puberty has been observed in the last decades. As genetic factors require long time to exert their effect, other players, such as environmental ones, may be involved. Special focus has been posed on nutritional status, endocrine-disrupting chemicals with non-conclusive results. Pubertal timing deeply affects future life, suggesting the need to clarify mechanisms driving pubertal onset and progression, in order to identify tailored therapeutic strategies and targets.
Asunto(s)
Herencia , Pubertad Precoz , Relojes Biológicos , Genes Supresores de Tumor , Humanos , Pubertad , Pubertad Precoz/genética , Ubiquitina-Proteína LigasasRESUMEN
BACKGROUND: Pseudohypoparathyroidism (PHP) represents a heterogeneous group of rare endocrine disorders caused by (epi) genetic abnormalities affecting the GNAS locus. It is mainly characterized by resistance to PTH and TSH, and by peculiar clinical features such as short stature, obesity, cognitive impairment, subcutaneous ossifications and brachydactyly. Delayed puberty, GHRH and calcitonin resistances have also been described. The healthcare-pathway recently proposed by the Italian Society of Pediatric Endocrinology and Diabetology (ISPED) has provided a standardized clinical approach to these conditions. The purpose of the present study was to evaluate its application in clinical practice, and to collect data for setting future specific studies. METHODS: Through a semi-structured survey, based on the indications of the care-pathway, data on PHP clinical management were collected. The compilation of each data in the survey was read as an index of the adoption of the healthcare-pathway in clinical practice. RESULTS: In addition to the proposing Center, 4 Centers joined the study, thus obtaining a large collection of data on 48 PHP patients. Highest rates in the completion of data were obtained for diagnostic history, auxological measurements and subcutaneous ossifications evaluation. As expected, the availability of data for the other investigated fields was lower, coming from recent research studies. More information has been obtained on hormonal resistance classically involved in PHP (PTH, TSH, GHRH and GnRH) and on cognitive impairment, while a few data has been collected on bone mineral status, calcitonin levels and glucolipid metabolism. CONCLUSIONS: The presented data show that the ISPED healthcare-pathway could represent a valid tool both to confirm the clinical approach to PHP patients and to allow homogeneous data collection; however, it has not yet been fully adopted. The strengthening of the network among the major Italian Endocrine Centers will contribute to improve its application in clinical practice, optimizing the follow-up of these patients and increasing knowledge on PHP.
Asunto(s)
Vías Clínicas , Pautas de la Práctica en Medicina/estadística & datos numéricos , Seudohipoparatiroidismo/diagnóstico , Seudohipoparatiroidismo/terapia , Niño , Consenso , Femenino , Estudios de Seguimiento , Humanos , Italia , Masculino , Seudohipoparatiroidismo/clasificación , Encuestas y CuestionariosRESUMEN
Vitamin D deficiency is the most common cause of rickets mainly in breast-fed dark-skinned, African or Asian children receiving inadequate sunlight exposure. We report a case of a 1.5 year-old Afro-Italian male infant living in South Italy who came to our observation with the typical clinical picture of vitamin D deficiency rickets. The child was exclusively breast-fed for 8 months without vitamin D supplements. Owing to the rarity of vitamin D deficiency rickets in the South of Italy he underwent several investigations, which demonstrated the association with an abdominal ganglioneuroblastoma. To our knowledge, ganglioneuroblastoma has never been reported in association with vitamin D deficiency rickets. Although the association between these 2 rare conditions may be coincidental, the protective action of vitamin D against cancer suggests that vitamin D deficiency might have contributed to the development of ganglioneuroblastoma in our patient.
Asunto(s)
Neoplasias Abdominales/complicaciones , Ganglioneuroblastoma/complicaciones , Raquitismo/etiología , Deficiencia de Vitamina D/complicaciones , Neoplasias Abdominales/fisiopatología , Neoplasias Abdominales/cirugía , Carbonato de Calcio/uso terapéutico , Procedimientos Quirúrgicos del Sistema Digestivo , Ganglioneuroblastoma/fisiopatología , Ganglioneuroblastoma/cirugía , Gluconatos/uso terapéutico , Humanos , Lactante , Masculino , Raquitismo/tratamiento farmacológico , Raquitismo/fisiopatología , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/tratamiento farmacológico , Deficiencia de Vitamina D/fisiopatologíaRESUMEN
Celiac disease (CD) is a T-cell-mediated enteropathy, triggered in genetically susceptible individuals by the ingestion of wheat gluten or related rye and barley proteins, whose clinical picture disease is considerably heterologous. Patients with CD are at high risk of autoimmune disorders; similarly, CD is frequent in patients with type 1 diabetes mellitus (T1DM), a disorder characterized by the immune-mediated beta-cell destruction, with the cooperation of environmental factors in genetically susceptible individuals. The immunological markers of beta-cell destruction are the autoantibodies to insulin, glutamic acid decarboxylase, and the protein tyrosine phosphatase. In absence of these markers, incidental hyperglycemia in children and adolescents appears unlikely to be associated with the progression to T1DM. We report a girl with CD and incidental hyperglycemia, without immunological markers of T1DM, with a family history for hyperglycemia, and diagnosed as maturity-onset diabetes of the young. We present this case as evidence that the possibility of monogenic forms of diabetes must be suspected in children with incidental hyperglycemia, a family history for mild hyperglycemia or diabetes, and absence of markers of beta-cell destruction, even if the patients are affected by an autoimmune disease.
Asunto(s)
Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/inmunología , Hiperglucemia/complicaciones , Hiperglucemia/inmunología , Autoanticuerpos , Enfermedades Autoinmunes , Biomarcadores , Glucemia/metabolismo , Enfermedad Celíaca/diagnóstico , Femenino , Predisposición Genética a la Enfermedad , Humanos , Hiperglucemia/diagnóstico , Factores de RiesgoRESUMEN
Studies like the DCCT and the UKPDS showed that prevention of Type 1 diabetes mellitus complications can be obtained if glucose level is maintained as close as possible to normal. Consequently management of diabetes has significantly changed in the last two decades since the aim of maintaining a good metabolic control has been pursued through intensive insulin therapy and self-monitoring blood glucose (SMBG). However, although SMBG is extremely helpful in preventing and treating hypoglycaemia and ketoacidosis, its role in maintaining a good metabolic control is controversial. Both the American Diabetes Association and the International Society for Paediatric and Adolescent Diabetes recommend the use of SMBG to maintain specific glycaemic levels but suggest that this is possible only if the patient achieves good skills in interpreting self-monitored data and consequently in self-adjusting insulin therapy and modifying eating and activity. Few studies have addressed this question and almost no data is available on SMBG and metabolic control in children with T1DM. However it can be stated that SMBG, although considered a cornerstone in diabetes care, is a necessary but not sufficient tool for the patient to achieve self-management and that only self-management leads to a good metabolic control. Paediatric diabetologists have a crucial role in providing long-term, continuative education in the use of SMBG and in self-management of diabetes.
Asunto(s)
Automonitorización de la Glucosa Sanguínea , Diabetes Mellitus Tipo 1/sangre , Adolescente , Glucemia/análisis , Niño , Preescolar , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Femenino , Humanos , Lactante , Insulina/administración & dosificación , Insulina/uso terapéutico , Italia , Masculino , Metaanálisis como Asunto , Estudios Multicéntricos como Asunto , Educación del Paciente como Asunto , Guías de Práctica Clínica como Asunto , Control de CalidadRESUMEN
We found significant elevated incidence of hypospadias in two towns in Southeastern Sicily selected on the basis of the presence of intense industrial (Augusta) and agricultural (Vittoria) activities. Cases and controls were chosen in records collected from a surveillance system on abnormal live births in the same area and in a large city (Catania) located in an area at low risk of exposure to environmental pollutants. From 1991 to 1998, 16 cases of isolated hypospadias were recorded among male live births in Augusta (12.1 per 1000 male live births) and 24 cases in Vittoria (7.4 per 1000 male live births) with an incidence significantly higher than that expected (3.2 per 1000 in Southeastern Sicily). Relative risks in Augusta and Vittoria were 3.8 (95% confidence interval: 2.16-6.14) and 2.3 (95% confidence interval: 1.48-3.43; P=0.00003 and 0.04, respectively). In Augusta, the incidence of hypospadias was higher than in Vittoria. Significant log odds ratios were found for occupational exposure in fathers both in Augusta and Vittoria (P=0.0478 and 0.026, respectively). However, daily contact with pollutants in Augusta may not be sufficient by itself to determine hypospadias and other factors might be involved. Similar factors may act also in Vittoria. Thus, contact with large amounts of pesticides is, by itself, a risk factor for hypospadias, though genetic and other environmental factors might be involved.
Asunto(s)
Agricultura , Anomalías Congénitas/etiología , Hipospadias/epidemiología , Exposición Profesional , Plaguicidas/efectos adversos , Estudios de Casos y Controles , Intervalos de Confianza , Factores de Confusión Epidemiológicos , Anomalías Congénitas/epidemiología , Femenino , Humanos , Incidencia , Italia/epidemiología , Masculino , Embarazo , Resultado del Embarazo , Sistema de Registros , Estudios Retrospectivos , Riesgo , Población Urbana/estadística & datos numéricosRESUMEN
Topics concerning quality of life in children and adolescents with Type 1 Diabetes Mellitus (T1DM) and summer camps, have only recently appeared in the scientific literature. Interest in quality of life in diabetic patients has lately increased. The Hvidore study group has recruited 2000 patients from several countries and has published an important paper whose conclusions suggest that T1DM patients have a better quality of life if they have a good metabolic control. The aim of this paper is to evaluate if summer camps, seen as an educational and therapeutic tool, can improve quality of life by increasing knowledge and self-management capacities. Certainly summer camps help T1DM children and adolescents to understand that they can be on vacations, practice sports, have fun with other children away from home and parents, just like every other child and adolescent. At summer camps T1DM patients become aware of not being the only ones to deal with the problem of diabetes; in addition parents become aware of their child's skills in the disease management and lastly improve the relationship with the medical staff who will have the opportunity of living an extremely important training experience. The more ambitious aim of summer camps, i.e. the gaining of knowledge and self-management skills and improvement in metabolic control, seems difficult to achieve. The limited literature available suggests that it is unlikely that one or more summer camps will contribute to the improvement of metabolic control; nevertheless, it is not easy to make such evaluations with scientific criteria. We think that Italian guidelines for summer camps should help in standardizing the organization and management; in this way it will be probably easier to evaluate the impact of summer camps on the quality of life.
Asunto(s)
Acampada , Diabetes Mellitus Tipo 1/psicología , Calidad de Vida , Adolescente , Actitud Frente a la Salud , Niño , Diabetes Mellitus Tipo 1/rehabilitación , Femenino , Objetivos , Guías como Asunto , Conocimientos, Actitudes y Práctica en Salud , Vacaciones y Feriados , Humanos , Italia , Masculino , Educación del Paciente como Asunto , Relaciones Profesional-Paciente , Evaluación de Programas y Proyectos de Salud , AutocuidadoRESUMEN
BACKGROUND: Primary adrenocortical insufficiency or Addison's disease is caused by a progressive destruction of the adrenal cortex, resulting into a reduction of glucocorticoids, mineralocorticoids, and androgens. Autoimmune Addison's disease is the most common etiological form, accounting for about 80% of all cases. CASE PRESENTATION: We describe the case of a 16-year-old Caucasian boy affected by type-1 diabetes mellitus and autoimmune thyroiditis, who experienced recurrent hypoglycaemia as presenting symptom of Addison's disease. CONCLUSIONS: Hypoglycaemia is not a common presenting feature of Addison's disease, both in patients with type-1 diabetes mellitus and in non-diabetic patients. However, hypoglycaemia may occur in association with primary and secondary glucocorticoid deficiency as a result of an enhanced insulin sensitivity. Hypoglycaemia is the most common acute complication of insulin therapy in patients with type-1 diabetes mellitus. Addison's disease has been described in approximately 0.5% of patients with type-1 diabetes mellitus, being more frequent in females and occurring in middle-aged patients. An association among type-1 diabetes mellitus, autoimmune thyroiditis, and Addison's disease is found in the "Schmidt's syndrome", a rare disorder that may occur in the paediatric age. Our case suggests that the presence of Addison's disease should be taken into consideration in patients with type-1 diabetes mellitus and frequent episodes of hypoglycaemia. We wish to highlight that there are no specific indications to screen for the association between Addison's disease and type-1 diabetes mellitus, although an early diagnosis of Addison's disease in diabetic patients would prevent the morbidity and potential mortality of this association.
Asunto(s)
Enfermedad de Addison/complicaciones , Diabetes Mellitus Tipo 1/complicaciones , Hipoglucemia/complicaciones , Adolescente , Humanos , Masculino , RecurrenciaRESUMEN
Neonatal diabetes mellitus (NDM) results from impaired insulin secretion, occurring within the first 6 months of life. NDM is classified as transient NDM (TNDM) or permanent NDM. To date there are no universal guidelines regarding its management. Intravenous insulin infusion represents the first and most adequate therapeutic approach for sustained hyperglycemia, but this can provide only a short-term solution. Several factors should be taken into account in the choice of the long-term treatment. We describe our experience with two infants affected by TNDM. The first child was treated with continuous subcutaneous insulin infusion, whereas the second infant was treated with subcutaneous insulin glargine injections. Our experience shows that the two different therapeutic approaches, if properly managed, are equally effective.
Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Hiperglucemia/prevención & control , Hipoglucemia/prevención & control , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Medicina de Precisión , Diabetes Mellitus/sangre , Femenino , Humanos , Hipoglucemia/inducido químicamente , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/efectos adversos , Recién Nacido , Inyecciones Subcutáneas , Insulina/administración & dosificación , Insulina/efectos adversos , Insulina Glargina , Sistemas de Infusión de Insulina , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/efectos adversos , Insulina de Acción Prolongada/uso terapéutico , Italia , Resultado del TratamientoRESUMEN
BACKGROUND/AIMS: Congenital hyperinsulinism of infancy is a rare disease that needs prompt treatment to avoid brain damage. There are currently no data regarding the clinical and molecular features of Italian patients. METHODS: Thirty-three patients with HI and their parents were included. Consanguinity was reported in six patients. Half of patients were macrosomic at birth. None had raised 3-hydroxybutyrylcarnitine or hyperammonemia. Molecular analysis of ABCC8 and KCNJ11 genes was performed in all patients, and subjects with no mutation underwent analysis of HNF4A and GCK. GLUD1 and HADH genes were analyzed in a patient with leucine sensitivity. RESULTS: Mutations in the ABCC8 and KCNJ11 genes were found in 45% of the patients (6 novel). No mutations in HNF4A, GLUD1 and GCK genes were found. Recessive mode of inheritance was found in 21% of patients. A single heterozygous mutation was identified in 24% of probands. 72% of the patients were responsive to medical treatment, and 44% of the 17 patients with no identified mutation achieved spontaneous remission. Nine children, unresponsive to medical therapy, underwent pancreatectomy. CONCLUSION: This is the first report on hyperinsulinism of infancy in Italy, confirming the complexity of the clinical forms and the heterogeneity of the genetic causes of the disease.
Asunto(s)
Hiperinsulinismo Congénito/genética , Canales de Potasio de Rectificación Interna/genética , Receptores de Sulfonilureas/genética , Hiperinsulinismo Congénito/cirugía , Consanguinidad , Femenino , Genes Recesivos , Humanos , Italia , Masculino , Pancreatectomía , Remisión EspontáneaRESUMEN
Congenital hyperinsulinism of infancy (CHI) is a rare disorder characterized by severe hypoglycemia due to inappropriate insulin secretion. The genetic causes of CHI have been found in genes regulating insulin secretion from pancreatic ß-cells; recessive inactivating mutations in the ABCC8 and KCNJ11 genes represent the most common events. Despite the advances in understanding the molecular pathogenesis of CHI, specific genetic determinants in about 50 % of the CHI patients remain unknown, suggesting additional locus heterogeneity. In order to search for novel loci contributing to the pathogenesis of CHI, we combined a family-based association study, using the transmission disequilibrium test on 17 CHI patients lacking mutations in ABCC8/KCNJ11, with a whole-exome sequencing analysis performed on 10 probands. This strategy allowed the identification of the potential causative mutations in genes implicated in the regulation of insulin secretion such as transmembrane proteins (CACNA1A, KCNH6, KCNJ10, NOTCH2, RYR3, SCN8A, TRPV3, TRPC5), cytosolic (ACACB, CAMK2D, CDKAL1, GNAS, NOS2, PDE4C, PIK3R3) and mitochondrial enzymes (PC, SLC24A6), and in four genes (CSMD1, SLC37A3, SULF1, TLL1) suggested by TDT family-based association study. Moreover, the exome-sequencing approach resulted to be an efficient diagnostic tool for CHI, allowing the identification of mutations in three causative CHI genes (ABCC8, GLUD1, and HNF1A) in four out of 10 patients. Overall, the present study should be considered as a starting point to design further investigations: our results might indeed contribute to meta-analysis studies, aimed at the identification/confirmation of novel causative or modifier genes.
Asunto(s)
Hiperinsulinismo Congénito/genética , Exoma , Genoma Humano , Polimorfismo de Nucleótido Simple , Femenino , Predisposición Genética a la Enfermedad , Técnicas de Genotipaje , Humanos , Insulina/metabolismo , Secreción de Insulina , MasculinoRESUMEN
By retrospectively collecting data from nine Italian centres of pediatric endocrinology, we assessed the different management and final outcome of children with short stature and idiopathic delayed puberty. Data were obtained in 77 patients (54 males, 23 females) diagnosed and followed-up in the various centres during the last 15 years. Inclusion criteria were short stature at initial observation and idiopathic delayed puberty diagnosed during follow-up. At first observation, age was 13.8 +/- 1.0 years and height standard deviation score (SDS) was -2.6 +/- 0.6 in males. In females age was 13.1 +/- 0.9 years and height SDS -2.6 +/- 0.4. Local diagnostic and therapeutic protocols included testing for growth-hormone deficiency (six centres) and treatment in case of deficiency or, in the remaining centres, testosterone or no treatment in males, and no treatment in females. At diagnosis, both in males and in females, the auxological features (height SDS, target height SDS and bone age delay) were similar in the patients treated with growth hormone, testosterone or not treated. Overall 32 patients received growth hormone (25 males, 7 females), 33 no treatment (17 males, 16 females) and 12 testosterone. There was no difference in the adult height of males and females in the different treatment groups. In males there were no differences between adult and target height SDSs (growth hormone-treated 0.31 +/- 0.79, untreated 0.10 +/- 0.82, testosterone-treated 0.05 +/- 0.95), between adult and initial height SDSs (growth hormone-treated 1.70 +/- 0.93, untreated 1.55 +/- 0.92, testosterone-treated 1.53 +/- 1.43) and percentage of subjects with adult height above target height. In females, there were no differences between adult and target height SDSs (growth hormone-treated -0.49 +/- 1.13; untreated 0.10 +/- 0.97) and between adult and initial height SDSs (growth hormone-treated 1.76 +/- 0.92; untreated 1.77 +/- 0.98), whereas a significantly higher percentage of patients remained below target height in the growth hormone-treated group (6/7, 85.7% vs 5/11, 31.3%) (P = 0.02). In conclusion, the diagnostic and therapeutic management of the patients with short stature and delayed puberty is different among Italian pediatric endocrinologists. Our data do not support the usefulness of growth-hormone therapy in improving adult height in subjects with short stature and delayed puberty, particularly in the female sex.
Asunto(s)
Estatura , Hormona de Crecimiento Humana/uso terapéutico , Pubertad Tardía/tratamiento farmacológico , Testosterona/uso terapéutico , Femenino , Estudios de Seguimiento , Trastornos del Crecimiento/fisiopatología , Trastornos del Crecimiento/terapia , Hormona de Crecimiento Humana/deficiencia , Humanos , Italia , Masculino , Pubertad Tardía/diagnóstico , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
BACKGROUND AND OBJECTIVES: Growth retardation and short stature are frequent clinical features of patients with beta-thalassaemia major. Dysfunction of the GH-IGF-1 axis has been described in many thalassaemic children and adolescents with short stature and reduced growth velocity. Several studies have demonstrated that recombinant GH treatment improves growth velocity in these patients, although response to the treatment is variable and not predictable. A reassessment of the GH-IGF-1 axis must be performed in young adults with childhood-onset GH deficiency (GHD), after attainment of final height, to select those who are candidates for replacement therapy as adults. To our knowledge there are no data available on retesting the GH-IGF-1 axis in adult thalassaemic patients with childhood-onset GHD. The aim of our study was to investigate GH secretion in adult thalassaemic patients with childhood-onset GHD. DESIGN: We reassessed GH secretion in a group of adult thalassaemic patients in whom partial GHD had been diagnosed during childhood. PATIENTS AND METHODS: We performed an arginine plus GH-releasing hormone (GHRH) stimulation test in 16 thalassaemic patients (10 males, six females) with a mean age of 24.8 +/- 3.6 years. The cut-off level for GH response was set at 9 microg/l, according to the literature. Ferritin, IGF-1, liver enzymes and lipid levels were also determined. RESULTS: We found persisting GHD in three patients, one patient had borderline values (GH peak = 10.4 microg/l), whereas the others had a normal response. These results are in accordance with the data on GH retesting in adult patients with idiopathic partial childhood-onset GHD. CONCLUSION: We conclude that GH status should be retested in adult thalassaemic patients with childhood-onset GHD. If the diagnosis of adult GHD is established, GH treatment may be considered as it could contribute to improve heart function and bone mineral density, which are frequently impaired in adult thalassaemic patients.
Asunto(s)
Hormona del Crecimiento/deficiencia , Talasemia/sangre , Adolescente , Adulto , Edad de Inicio , Arginina , Femenino , Ferritinas/sangre , Hormona del Crecimiento/sangre , Hormona Liberadora de Hormona del Crecimiento , Humanos , Factor I del Crecimiento Similar a la Insulina/análisis , Lípidos/sangre , MasculinoRESUMEN
BACKGROUND: Many factors can negatively affect growth in thalassemic patients, and hypogonadism has been considered as the main factor responsible for their pubertal growth failure. OBJECTIVE: To evaluate the influence of hypogonadism and its treatment on pubertal growth and final height in thalassemic patients. METHODS: We compared the growth of 28 hypogonadal thalassemic patients in whom puberty was induced to that of 25 patients in whom puberty occurred spontaneously. RESULTS: In both groups of patients we observed reduced peak height velocity (induced puberty: females 4.9 +/- 2.1, males 6.0 +/- 1.8 cm/year; spontaneous puberty: females 6.1 +/- 1.5, males 7.3 +/- 2.1 cm/year) and pubertal height gain (induced puberty: females 11.3 +/- 4.0, males 18.0 +/- 4.5 cm/year; spontaneous puberty: females 15.8 +/- 2.7, males 18.1 +/- 5.3 cm/year) and a short final height (induced puberty: females -1.8 +/- 0.7, males -2.1 +/- 1.0 SDS; spontaneous puberty: females -2.3 +/- 1.0, males -1.9 +/- 1.0 SDS). CONCLUSIONS: Poor pubertal growth is present in thalassemic patients regardless of hypogonadism. Other factors are responsible for the reduced growth spurt and the final short stature observed in these patients.